CelAgace™ OraRinse Solution for Treatment of Candidiasis

Status Not yet recruiting

Clinical Trial Summary

CelAgace™ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated with mouth sores.

Clinical Trial Description

CelAgace™ contains two active ingredients, a silver citrate complex salt (0.01mg/ml) that has demonstrated laboratory effectiveness against yeast organisms and acemannan (4.0mg/ml), a purified extract isolated from the inner leaf gel of the Aloe vera plant that has been used as a key ingredient in other oral care products. Patients will swish and spit the product 4 times daily (after meals and at bedtime) for 14 days. Following an initial office visit, patients will be evaluated on days 7 and 14 to determine response to the product. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03250923
Study type	Interventional
Source	CelaCare Technologies, Inc.
Contact	Jacqueline M. Plemons, DDS, MS
Phone	214-828-8467
Email	jplemons@tamhsc.edu
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	September 2024
Completion date	May 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00004781` - Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups	N/A
Completed	`NCT03894839` - Evaluation of the Effect of Different Cleaning and Disinfection Procedures on the Involvement of Candida Species	N/A
Completed	`NCT00128323` - A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis	Phase 3
Recruiting	`NCT04410250` - Effect of Oral Hygienization in Newborn on Candida Spp Colonization	N/A
Completed	`NCT02184351` - Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis	Phase 3
Recruiting	`NCT03873753` - Relationship Between Oral Hygiene in Newborns and Candida Spp.	N/A
Completed	`NCT00665639` - Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis	Phase 3
Completed	`NCT02818803` - Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic	Phase 3
Active, not recruiting	`NCT06120816` - Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis	Phase 1
Completed	`NCT00235053` - Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID	Phase 4
Completed	`NCT00666185` - Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis	Phase 3
Completed	`NCT00002446` - Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients	Phase 3
Completed	`NCT00001448` - The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection	N/A
Completed	`NCT00612963` - Novel Rinse to Treat in Oral Candidiasis in Cancer Patients	N/A
Completed	`NCT00001812` - A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2	Phase 3
Completed	`NCT00002293` - A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes	N/A
Completed	`NCT00002057` - Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC	N/A
Completed	`NCT00001065` - A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole	Phase 2
Completed	`NCT00002133` - An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.	N/A
Completed	`NCT00002112` - Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome	N/A